Biogen pays $900M to settle wide-ranging physician kickback claims
Looking to clear the deck ahead of its long-awaited lecanemab data release, Biogen agreed to pay the US government and states a whopping $900 million to settle seven-year-old allegations that it submitted false claims to Medicare and Medicaid by paying kickbacks to physicians to induce them to prescribe Biogen drugs.
The settlement, which is on the higher end of these DOJ-related resolutions that have become common in the pharma industry, resolves a lawsuit filed by former Biogen employee (now a director at Genzyme) Michael Bawduniak, who will take home almost $250 million as part of the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
